Related Experiment Video
Updated: May 19, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
[Peripheral dendritic cell subsets and changes in plasma monocyte chemoattractant protein 1 in patients with coronary
Zikai Sun1, Wenliang Zhong, Yiming Qiu
1Department of Cardiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. ssarah@126.com
Insights
Monocyte chemoattractant protein 1 (MCP-1) levels are elevated in coronary heart disease (CHD) patients. Higher MCP-1 correlates with lower myeloid dendritic cells (mDCs), suggesting a role in plaque instability.
Area of Science:
- Immunology
- Cardiovascular Medicine
Context:
- Coronary heart disease (CHD) involves complex immune and inflammatory processes.
- Dendritic cells (DCs) play a crucial role in immune regulation and inflammation.
- Monocyte chemoattractant protein 1 (MCP-1) is a key chemokine in inflammatory responses.
Purpose:
- To investigate the relationship between peripheral blood dendritic cell subtypes and plasma MCP-1 levels in CHD patients.
- To explore the potential role of MCP-1 in the pathogenesis of CHD.
Summary:
- Peripheral blood myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs) were significantly reduced in acute myocardial infarction (AMI) and unstable angina pectoris (UAP) patients compared to controls and stable angina pectoris (SAP) patients.
- CHD patients exhibited higher plasma MCP-1 levels than controls.
- A significant inverse correlation was observed between plasma MCP-1 concentration and the percentage of peripheral mDCs in CHD patients.
Impact:
- Findings suggest MCP-1 may drive mDC migration into atherosclerotic plaques.
- MCP-1 potentially exacerbates local immune and inflammatory responses, contributing to plaque instability in CHD.
- This research highlights a potential therapeutic target for managing CHD progression.
Objective:
To assess the association between peripheral blood dendritic cells subtype distribution and plasma monocyte chemoattractant protein 1 (MCP-1) concentration in patients with coronary heart disease (CHD).
Methods:
Sixty consecutive CHD patients admitted in our department during the period from November, 2010 to December, 2011 were enrolled, including 10 with stable angina pectoris (SAP), 25 with unstable angina pectoris (UAP), and 25 with acute myocardial infarction (AMI), with 28 healthy volunteers as normal controls. All the subjects underwent routine tests and coronary angiography. The percentages of peripheral blood myeloid dendritic cells (mDCs) and plasma cell-like dendritic cells (pDCs) in peripheral blood mononuclear cells were detected by flow cytometry, and plasma MCP-1 levels were detected using enzyme-linked immunosorbent assay.
Results:
The percentage and absolute quantity of mDCs and pDCs were significantly lower in AMI and UAP groups than in the normal control and SAP groups (P<0.001). In the CHD patients, the plasma MCP-1 level was significantly higher than that in the normal control group (P<0.001) with an inverse correlation with the percentage of peripheral mDCs.
Conclusion:
MCP-1 may promote the migration of mDCs into atherosclerotic plaques and mediate the local immune and inflammatory responses to aggravate plaque instability in CHD patients.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:15Differentiation of Common Myeloid Progenitor Cells